TOMI Environmental Solutions, Inc. Awarded Group Purchasing Agreement With Premier
BEVERLY HILLS, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (“TOMI”) (OTCQX:TOMZ), a global decontamination company that specializes in disinfection/decontamination sales and services, including SteraMist™, a hydrogen peroxide-based mist/fog registered with the U.S. Environmental Protection Agency (“EPA”) for use as a hospital-healthcare disinfectant, was added to the list of approved suppliers for the healthcare improvement company, Premier, effective November 3rd.
Group purchasing organizations (GPOs) were originally established to pool the purchasing power of hospitals and other healthcare providers in order to receive significant discounts on much needed medical supplies. Premier, which operates a leading GPO, unites thousands of U.S. hospitals and more than 150,000 additional provider organizations. For TOMI™, this inclusion offers another opportunity to further penetrate the hospital healthcare market.
This multi-use, broad-based technology can be incorporated into all areas of a hospital environment and many hospitals across the country have already successfully integrated the SteraMist technology into their routine cleaning protocols. SteraMist is currently on the EPA’s List K for Registered Antimicrobial Products. Additionally, TOMI™ has met the requirements and submitted to be included on EPA Lists L and M.
TOMI is excited to start building a mutually beneficial relationship with the Premier network to deliver the best disinfection technology on the market today. Elissa Shane, Operations and Compliance Officer for TOMI, stated, “We are excited to join Premier’s supplier list and are committed to delivering the best products with the best value to its members.”
About TOMI Environmental Solutions, Inc.
TOMI Environmental Solutions, Inc. (OTCQX:TOMZ) is a global decontamination and infection prevention company, providing environmental solutions for indoor surface disinfection through manufacturing, sales and licensing of its premier Binary Ionization Technology® (BIT™) platform, which was invented under a defense grant in association with the Defense Advanced Research Projects Agency (DARPA) of the U.S. Department of Defense. BIT™ uses a low percentage Hydrogen Peroxide as its only active ingredient to produce a hydroxyl radical (OH ion), represented by the TOMI™ SteraMist™ brand of products, which produces a germ-killing aerosol that works like a visual non-caustic gas.
TOMI’s products are designed to service a broad spectrum of commercial structures including but not limited to hospitals and medical facilities, cruise ships, office buildings, hotel and motel rooms, schools, restaurants, meat and produce processing facilities (when not in operation), military barracks, police and fire departments, and athletic facilities. TOMI’s products and services have also been used in single-family homes and multi-unit residences.
TOMI also develops training programs and application protocols for its clients and is a member in good standing of The American Biological Safety Association, The American Association of Tissue Banks, Association for Professionals in Infection Control and Epidemiology, Society for Healthcare Epidemiology of America and The Restoration Industry Association.
For additional information, please visit http://www.tomimist.com/ or contact us at info@tomimist.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995
Certain written and oral statements made by us may constitute “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). Forward-looking statements are identified by such words and phrases as “we expect,” “expected to,” “estimates,” “estimated,” “current outlook,” “we look forward to,” “would equate to,” “projects,” “projections,” “projected to be,” “anticipates,” “anticipated,” “we believe,” “could be,” and other similar phrases. All statements addressing operating performance, events, or developments that we expect or anticipate will occur in the future, including statements relating to revenue growth, earnings, earnings-per-share growth, or similar projections, are forward-looking statements within the meaning of the Reform Act. They are forward-looking, and they should be evaluated in light of important risk factors that could cause our actual results to differ materially from our anticipated results. The information provided in this document is based upon the facts and circumstances known at this time. We undertake no obligation to update these forward-looking statements after the date of this release
MEDIA RELATIONS CONTACT
Juliana deRosa
Executive Administrator
jderosa@tomimist.com